Influenza News and Research

Latest Influenza News and Research

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Results from a new study suggest that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology

24 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

UT Southwestern biochemist Dr. Zhijian "James" Chen today was named winner of the prestigious 2019 Breakthrough Prize in Life Sciences for his discovery of the cGAS enzyme that launches the body's immune defense against infections and cancers.

19 Oct 2018

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades.

18 Oct 2018

Researchers develop new techniques for faster detection of Lyme disease bacteria

Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

11 Oct 2018

NIR spectroscopy could be used to make flu vaccine manufacturing faster and more efficient

Recent research from North Carolina State University outlines how near-infrared spectroscopy could be used to make cell-culture-based flu vaccine manufacturing faster and more efficient.

11 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Researchers at Rutgers Robert Wood Johnson Medical School have identified an important step in the process that allows our bodies to fight viruses.

2 Oct 2018

Scientists investigate effect of flu-causing virus on three lung-derived cell lines

Perhaps inspired by the annual 3 to 5 million cases of severe influenza worldwide, the Guinness World Record organization is advertising for individuals or organizations to attempt a record for the most people getting a flu awareness lesson at once.

29 Sep 2018

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than one billion people--more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

27 Sep 2018

New approach to vaccine development and improved surveillance could help target deadly diseases

Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.

26 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Old letters provide insight into Spanish flu pandemic horror

An archive of letters written by those who survived the Spanish flu pandemic at the start of the last century shows what it was actually like to live during that time. The Spanish flu pandemic killed over 250,000 people in Britain alone and worldwide it wiped out a population of over 100 million.

23 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Researchers demonstrate pre-clinical success for universal flu vaccine in new paper

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

21 Sep 2018

Influenza News and Research

Latest Influenza News and Research

FDA approves new antiviral flu treatment

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers develop new techniques for faster detection of Lyme disease bacteria

NIR spectroscopy could be used to make flu vaccine manufacturing faster and more efficient

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Scientists investigate effect of flu-causing virus on three lung-derived cell lines

NIAID releases strategic plan to expand knowledge of TB by using modern tools

New approach to vaccine development and improved surveillance could help target deadly diseases

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Old letters provide insight into Spanish flu pandemic horror

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

Researchers demonstrate pre-clinical success for universal flu vaccine in new paper

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Influenza News and Research

Latest Influenza News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in